Molecular Devices releases ImageXpress HCS.ai system for automated drug discovery
Molecular Devices has introduced the ImageXpress HCS.ai Advanced Duo, a dual-camera imaging system designed to integrate data acquisition and AI-driven analysis into a single screening workflow.
Molecular Devices, a subsidiary of Danaher Corporation, has launched the ImageXpress HCS.ai Advanced Duo, a platform designed to accelerate high-content screening processes in drug discovery. The system utilizes dual-camera technology to synchronize image acquisition with AI-enabled data processing, aiming to reduce the time spent moving samples between separate analysis stages.
By consolidating image capturing and computational analysis into one workflow, the system seeks to eliminate manual handoffs that often cause bottlenecks in research laboratories. The integration of specialized screening analytics allows researchers to automate complex imaging tasks, potentially increasing throughput for large-scale pharmaceutical trials.
This release reflects the broader industry movement toward automating laboratory workflows through artificial intelligence to shorten development cycles. As pharmaceutical companies face pressure to lower costs and reduce R&D timelines, the adoption of integrated imaging systems is becoming a standard operational goal for internal research units.